Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction

Journal of Clinical Pharmacology

Volumn 52, Issue 9, 2012, Pages 1296-1305

  Tisdale, James E ^a,b   Overholser, Brian R ^a,b   Wroblewski, Heather A ^a   Sowinski, Kevin M ^a,b   Amankwa, Kwadwo ^a   Borzak, Steven ^c   Kingery, Joanna R ^b   Coram, Rita ^b   Zipes, Douglas P ^b   Flockhart, David A ^b   Kovacs, Richard J ^b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Arrhythmias; heart failure; pharmacodynamics; QT interval; torsades de pointes

Indexed keywords

AMIODARONE; IBUTILIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE BIGEMINY; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; QT PROLONGATION; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; FEMALE; HEART FAILURE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; SULFONAMIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84866043721     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011416939     Document Type: Article

References (34)

1. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007 ; 153: 891-899
2. Tisdale JE Drug-Induced Diseases: Prevention, Detection and Management. 2 nd ed.Bethesda, Maryland: American Society of Health-System Pharmacists; 2010:485-515. Tisdale JE Miller DA, ed. Bethesda, Maryland: American Society of Health-System Pharmacists ; 2010: 485-515.
3. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veteran Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998 ; 98: 2574-2579
4. Hynes BJ, Luck JC, Wolbrette DL, et al. Atrial fibrillation in patients with heart failure. Curr Opin Cardiol. 2003 ; 18: 32-38
5. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 ; 82: 2N - 9N
6. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003 ; 107: 2920-2925
7. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000 ; 102: 2385-2390
8. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999 ; 341: 857-865
9. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996 ; 28: 130-136
10. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation. 1997 ; 96: 4298-4306
11. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998 ; 31: 1414-1419
12. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996 ; 94: 1613-1621
13. Stambler BS, Beckman KJ, Kadish AH, et al. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol. 1997 ; 80: 458-463
14. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996 ; 94: 2534-2541
15. Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation. 1995 ; 91: 1799-1806
16. Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther. 1992 ; 262: 99-108
17. Tisdale JE, Overholser BR, Sowinski KM, et al. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction. Pharmacotherapy. 2008 ; 28: 1461-1470
18. Fridericia LS. Die systolendauer im elektrokardiogramm bei normalen menchen und bei herzkranken. Acta Med Scand. 1920 ; 53: 469-486
19. Hodges M. Rate correction of the QT interval. Card Electrophysiol Rev. 1997 ; 1: 360-363
20. D'Argenio DZ, Schumitzky A ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource ; 1997:
21. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 ; 6: 429-453
22. Kowey PR, VanderLugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol. 1996 ; 78: 46-52
23. Benowitz NL, Meister W. Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet. 1976 ; 1: 389-405
24. Näbauer M, Beuckelmann DJ, Erdmann E. Characteristics of transient outward current in human ventricular myocytes from patients with terminal heart failure. Circ Res. 1993 ; 73: 386-394
25. Kääb S, Dixon J, Duc J, et al. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation. 1998 ; 98: 1383-1393
26. Tomaselli GF, Marbán E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999 ; 42: 270-283
27. Beuckelmann DJ, Näbauer M, Erdmann E. Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res. 1993 ; 73: 379-385
28. Undrovinas AI, Maltsev VA, Sabbah HN. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci. 1999 ; 55: 494-505
29. Houser SR, Piacento V, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol. 2000 ; 32: 1595-1607
30. Kääb S, Nuss HB, Chiamvimonvat N, et al. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res. 1996 ; 78: 262-273
31. Pak PH, Nuss HB, Tunin RS, et al. Repolarization abnormalities, arrhythmias and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol. 1997 ; 30: 576-584
32. Haugaa KH, Amlie JP, Berge KE, Leren TP, Smiseth OA, Edvardsen T. Transmural differences in myocardial contraction in long-QT syndrome: mechanical consequences of ion channel dysfunction. Circulation. 2010 ; 122: 1355-1363
33. Cheng A, Dalal D, Fetics BJ, et al. Ibutilide-induced changes in the temporal lability of ventricular repolarization in patients with and without structural heart disease. J Cardiovasc Electrophysiol. 2009 ; 20: 873-879
34. Darbar D, Hardin B, Harris P, ]Roden DM. A rate-independent method of assessing QT-RR slope following conversion of atrial fibrillation. J Cardiovasc Electrophysiol. 2007 ; 18: 636-641